These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3865924)

  • 21. In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria.
    Rudrik JT; Cavalieri SJ; Britt EM
    Antimicrob Agents Chemother; 1984 Jul; 26(1):97-100. PubMed ID: 6591853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo antibacterial activity of AT-2266.
    Kouno K; Inoue M; Mitsuhashi S
    Antimicrob Agents Chemother; 1983 Jul; 24(1):78-84. PubMed ID: 6226242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.
    Blaser J; Stone BB; Groner MC; Zinner SH
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1054-60. PubMed ID: 3116917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The in-vitro activity of CI-934 compared with that of other new 4-quinolones and nalidixic acid.
    King A; Shannon K; Slegg J; Phillips I
    J Antimicrob Chemother; 1986 Aug; 18(2):163-9. PubMed ID: 3463557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enoxacin: a potent inducer of filamentous Escherichia coli cells (a note).
    Uri JV; Actor P
    Acta Microbiol Hung; 1985; 32(2):197-200. PubMed ID: 3933273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.
    Nakamura S; Minami A; Katae H; Inoue S; Yamagishi J; Takase Y; Shimizu M
    Antimicrob Agents Chemother; 1983 May; 23(5):641-8. PubMed ID: 6575721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of the 4-quinolones.
    Eggleston M; Park SY
    Infect Control; 1987 Mar; 8(3):119-25. PubMed ID: 3553053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative evaluation of enoxacin, ofloxacin, ampicillin, and chloramphenicol for treatment of experimental Haemophilus influenzae pneumonia.
    Kemmerich B; Borner K; Pennington JE
    Antimicrob Agents Chemother; 1987 Mar; 31(3):417-20. PubMed ID: 3495234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative evaluation of ciprofloxacin, enoxacin, and ofloxacin in experimental Pseudomonas aeruginosa pneumonia.
    Kemmerich B; Small GJ; Pennington JE
    Antimicrob Agents Chemother; 1986 Mar; 29(3):395-9. PubMed ID: 2940970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
    Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
    Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro antibacterial activity of enoxacin (CI-919).
    Fernandes CJ; Munro R; Toohey M; Shanker S; Mallon R; Daley D; Harland GS; Stevens DA; Wilson RD; Ackerman VP
    Pathology; 1986 Apr; 18(2):240-2. PubMed ID: 3093961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of medium and method on the in vitro susceptibility of Pseudomonas aeruginosa and other bacteria to ciprofloxacin and enoxacin.
    Blaser J; Dudley MN; Gilbert D; Zinner SH
    Antimicrob Agents Chemother; 1986 May; 29(5):927-9. PubMed ID: 2942102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vitro selection of bacteria resistant to the 4-quinolone agents.
    Limb DI; Dabbs DJ; Spencer RC
    J Antimicrob Chemother; 1987 Jan; 19(1):65-71. PubMed ID: 3470281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enoxacin: worldwide in-vitro activity against 22451 clinical isolates.
    Siporin C; Towse G
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():47-55. PubMed ID: 6594322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro activity of enoxacin, ofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Ullmann U
    J Antimicrob Chemother; 1984 Sep; 14 Suppl C():33-8. PubMed ID: 6238931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Susceptibility of Campylobacter species to nalidixic acid, enoxacin, and other DNA gyrase inhibitors.
    Taylor DE; Ng LK; Lior H
    Antimicrob Agents Chemother; 1985 Nov; 28(5):708-10. PubMed ID: 3004325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antibacterial activity of enoxacin in vitro and in urine].
    Soussy CJ; Deforges L; Duval J
    Pathol Biol (Paris); 1987 May; 35(5):475-81. PubMed ID: 3302849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1992)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Tanimoto H; Nakata K; Nakamori Y; Nakatani T; Kusano N
    Jpn J Antibiot; 1996 Jan; 49(1):34-70. PubMed ID: 8851305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.